Navigation Links
STALLERGENES: 2008: Strong Performance
Date:3/24/2009 

    ANTONY, France, March 24 /PRNewswire-FirstCall/ --
    - Strong Growth in Results Sales up 16%, net Profit up 17%
    - Sound Financial Position
    - Proposed Increase in Dividend

The Board of Directors, meeting on 23 March 2009 under the chairmanship of Albert SAPORTA, approved the 2008 consolidated financial statements:

    EUR millions                 2007         07/06      2008         08/07
                                    as % of       %         as % of       %
                                     sales   change          sales   change

    Sales                    147.1   100.0      16   170.9   100.0      16
    Cost of goods sold       (32.9)  (22.3)     11   (39.8)  (23.3)     21
    SG&A                     (65.1)  (44.3)     17   (72.9)  (42.7)     12
    R&D net                  (23.8)  (16.2)     32   (30.0)  (17.5)     26
    EBIT                      25.3    17.2       9    28.1    16.5      11
    Net profit, group share   16.3    11.1      12    19.0    11.1      17
    EBITDA                    30.0    20.4       9    34.3    20.1      14
    Capital expenditure      (16.2)  (11.0)     68   (18.3)  (10.7)     12
    Free cash flow             6.5     4.4     (19)    4.7     2.8     (28)
    Net financial debt        10.4             (14)    9.6              (8)
    Equity                    66.4              26    82.6              24
    EPS, diluted              1.22 EUR          10    1.43 EUR          17
    Proposed dividend         0.40 EUR          14    0.45 EUR          13

2008 sales grew by 16% to EUR 171 million, in line with the growth of previous financial years since 2000 (15% average annual growth). The sublingual route remained the main driver of this growth with an 18% increase over the financial year.

Operating profit totalled EUR 28.1 million, along with an operating margin of 16.5%. This performance was all the mo
'/>"/>

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
2. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
3. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
4. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
5. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
6. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
7. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
8. Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
9. BIO 2008: Germany on Cutting Edge in Biomanufacturing
10. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
11. Commencement 2008: Student innovation could improve data storage, magnetic sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...- Biomedical engineers at The University of Texas ...ave announced pre-clinical test results in the Sep...edicine demonstrating the feasibility of a smart p... in glucose or blood sugar levels and releases ins...tions of the pancreas which produces the blood-sug...
...nc. (Nasdaq:,SQNM) today announced that a live aud...l be provided for its analyst and investor briefin...the event are as follows: (Logo: http://www.new... Sequenom Today and Tomorrow, When: Monday...here: http://www.sequenom.com , How: Liv...
...l Alliance, the leading,management consulting firm...dustries, today announced that Ben Bonifant, Vice ...ent practice, will moderate a panel discussion,at ...rence hosted by,Windhover Information. The confere...iott Financial Center in New York City. The panel...
Other Biology Technology:Smart insulin nanostructures pass feasibility test, UT study reports 2Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24 2Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference 2Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference 3
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/4/2009)Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of h
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):How to read brain activity? 2U-Iowa study helps advance heart-related research 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Biopolymers Symposium 2009 Teams with Carbonfund org to Create a Zero Carbon Event 13295 1Biopolymers Symposium 2009 Teams with Carbonfund org to Create a Zero Carbon Event 13295 210 Steps to Affordable Health Care Overhaul 3A NCPA Proposes Reforms to Protect Choices Control Costs and Preserve Access 53252 110 Steps to Affordable Health Care Overhaul 3A NCPA Proposes Reforms to Protect Choices Control Costs and Preserve Access 53252 2Human Pheromones 3A Whats Purported Whats Supported A White Paper Published by The Sense of Smell Institute 53249 1
... for Medical Research (Burnham) have discovered a ... Sporadic Inclusion Body Myositis (sIBM). sIBM is ...men, causing muscles to gradually weaken and waste...known, but it is the most common muscle disease am...iliarity, it is probably underdiagnosed. This disc...
...cal Research Institute report that bats significan...In a lowland tropical rainforest in Panama, bats c...cts as do birds. This landmark study in the journa...ats and birds to protect plants via insect predati...dy by the authors suggested that bats were underes...
... University have pinpointed a small group of genes...w to produce a hormone that is key to their develo...ich hormone production in plants affects both a pl...nvironments. , Dr. Jose Alonso, assistant profes...nt biologists from NC State, Germany and the Czech...
Other Biology News:RING finger protein 5 may guide treatment for muscle disease in older adults 2RING finger protein 5 may guide treatment for muscle disease in older adults 3Smithsonian researchers show major role of bats in plant protection 2NC State researchers identify genes key to hormone production in plants 2
Rabbit Anti-QKI Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Acridinium Ester Trigger Solutions from Assay Designs/Stressgen Bioreagents
Mouse Anti-St. Louis encephalitis Monoclonal Antibody, Unconjugated, Clone 6B5A-2 from ABR-Affinity BioReagents
...bbit polyclonal to Kv4.2 Immunogen Synthetic pep...rresponding to amino acids 23-43 of Rat Kv4.2. Re...cted to cross-react with Human (100% identity with... Rabbit (100% identity with immunogen) and Ferret ...
Biology Products: